Rasmus Holm-Jorgensen
Director of Finance/CFO at ACRIVON THERAPEUTICS, INC.
Net worth: 230 875 $ as of 29/04/2024
Profile
Rasmus Holm-Jorgensen founded Kiniksa Pharmaceuticals Ltd.
in 2015, where he worked as Chief Strategy & Portfolio Officer from 2015 to 2022.
Mr. Holm-Jorgensen also currently works at Acrivon Therapeutics, Inc., as Chief Financial Officer from 2022.
Mr. Holm-Jorgensen also formerly worked at Synageva BioPharma Corp., as Group Vice President & General Manager from 2011 to 2015.
Mr. Holm-Jorgensen received his graduate degree from the University of Copenhagen.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 13/05/2024 | 27,258 ( 0.09% ) | 230 875 $ | 29/04/2024 |
Rasmus Holm-Jorgensen active positions
| Companies | Position | Start |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Director of Finance/CFO | 31/03/2022 |
Former positions of Rasmus Holm-Jorgensen
| Companies | Position | End |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Founder | 31/03/2022 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 31/12/2014 |
Training of Rasmus Holm-Jorgensen
| University of Copenhagen | Graduate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Rasmus Holm-Jorgensen
